Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Radiation showdown: which schedule beats childhood brain cancer?

NCT ID NCT01351870

Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tested two different ways of giving radiation to children and teens with a standard-risk brain tumor called medulloblastoma. One group got standard daily radiation, while the other got smaller doses twice a day. The goal was to see which schedule better prevents the cancer from coming back. The study enrolled 52 participants aged 4 to 21.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Radiation therapy
What this could lead to
If successful, this could identify a more effective radiotherapy schedule for children with medulloblastoma, potentially improving disease control and survival.
What could go wrong
This is a completed Phase 3 trial with only 52 participants, so results may not apply broadly. Both regimens involve radiation, which carries risks of long-term side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

52 people

The number who actually took part.

Start date

Apr 2004

Finished

Mar 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 22 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age at diagnosis at least 4 years or 5 years (according to the policy of the National Brain Tumour Group) and less than 22 years. * Histologically proven medulloblastoma, including the following variants(WHO classification - 2000): classic medulloblastoma, nodular / desmoplastic medulloblastoma, melanotic medulloblastoma, medullomyoblastoma No CNS metastasis on MRI - supratentorial, arachnoid of the posterior fossa or spine. * No clinical evidence of extra-CNS metastasis * No tumour cells on the cytospin of lumbar CSF. Central Review of CSF cytology is recommended but not mandatory. It will be left to national policy. * Radiotherapy to start no more than 40 days after surgery. * Ability to receive twice daily radiotherapy. * Vital functions within normal range for their age group. * CTC grades \< 2 for liver, renal, haematological and audiological function. * No medical contraindication to radiotherapy or chemotherapy. * Written informed consent (and patient assent where appropriate) according to the laws of each participating country. Written informed consent should also be sought for biological studies. * National and local ethical committee approval according to the laws of each participating country (to include approval for biological studies). Exclusion Criteria: * One of the inclusion criteria is lacking. * Brainstem or supratentorial primitive neuroectodermal tumour. * Atypical teratoid rhabdoid tumour. * Medulloepithelioma. * Ependymoblastoma. * Large cell médulloblastoma. * Metastatic medulloblastoma (on CNS MRI and/or positive cytospin of postoperative lumbar CSF). * Patient previously treated for a brain tumour or any type of malignant disease. * Patients who are pregnant. * Females who are sexually active and not taking reliable contraception. * Known predisposition to medulloblastoma e.g. Gorlin's syndrome.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Medulloblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

medulloblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Medulloblastoma

Contacts and locations

Locations

  • Institut Curie

    Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.